Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How do real tumors become resistant to cisplatin?

Cell cycle (Georgetown, Tex.) - 15 May 2008

Borst Piet, Rottenberg Sven, Jonkers Jos

Abstract excerpt

Lab research on cultured tumor cells selected for resistance to platinum compounds has turned up a diverse array of resistance mechanisms. In contrast, we recently found that mouse mammary tumors containing irrepairable null alleles of the Brca1 gene do not become resistant to cisplatin ever, although they invariably become resistant to a variety of other anti-cancer drugs. Each new treatment with cisplatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Genes, BRCA1

Share to Maximum Tolerated Dose

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 18418074
DOI: 10.4161/cc.7.10.5930

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

How do real tumors become resistant to cisplatin?PMID 18418074Read ↗

What Makes Tumors Multidrug Resistant?Semantic proximity Read ↗

Drug resistance in the mouse cancer clinicSemantic proximity Read ↗

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.Semantic proximity Read ↗

Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cellsSemantic proximity Read ↗

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivoSemantic proximity Read ↗

Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor TopotecanSemantic proximity Read ↗

Rapid Acquisition of Multicellular Drug Resistance After a Single Exposure of Mammary Tumor Cells to Antitumor Alkylating AgentsSemantic proximity Read ↗

DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells.Semantic proximity Read ↗

Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies.Semantic proximity Read ↗

Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines.Semantic proximity Read ↗

Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.